Who
Andrew Lo
Director
Company insider
Files Form 4 as: Director, BridgeBio Pharma; Director, AbCellera Biologics; Director, Roivant Sciences; 10% owner, Urovant Sciences; 10% owner, Myovant Sciences; 10% owner, Axovant Sciences; 10% owner, Arbutus Biopharma.
In numbers
- Trades disclosed
- 59
- Buys
- 33
- Sells
- 3
- Bought
- $127.6M
- Sold
- $10.2M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 16 Oct 2017
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 18 Nov 2025filed 19 Nov 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.6M24,007 at $65.23 | filing |
| 18 Nov 2025filed 19 Nov 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $2.0M30,993 at $66.05 | filing |
| 17 Nov 2025filed 19 Nov 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $2.5M36,801 at $66.63 | filing |
| 17 Nov 2025filed 19 Nov 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $255K3,798 at $67.06 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,425 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —6,589 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —238,864 at $0.00 | filing |
| 2 May 2025filed 6 May 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $3.9M100,000 at $38.50 | filing |
| 21 Jun 2024filed 25 Jun 2024 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,014 at $0.00 | filing |
| 21 Jun 2024filed 24 Jun 2024 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —163,934 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,501 at $0.00 | filing |
| 1 Dec 2022filed 5 Dec 2022 | ABCL AbCellera Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,231 at $0.00 | filing |
| 15 Sep 2022filed 19 Sep 2022 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —71,850 at $0.00 | filing |
| 15 Sep 2022filed 19 Sep 2022 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —52,142 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,921 at $0.00 | filing |
| 30 Dec 2021filed 3 Jan 2022 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Bought | $21K1,500 at $14.30 | filing |
News
Andrew locked in battle over evidence found through unlawful search warrantsecho-news.co.uk · 8 Oct 2026Andrew locked in battle over evidence found through unlawful search warrantstheargus.co.uk · 8 Oct 2026Andrew locked in battle over evidence found through unlawful search warrantsdunmowbroadcast.co.uk · 8 Oct 2026Andrew locked in battle over evidence found through unlawful search warrantsguardian-series.co.uk · 8 Oct 2026Andrew locked in battle over evidence found through unlawful search warrantsgreenocktelegraph.co.uk · 8 Oct 2026Andrew locked in battle over evidence found through unlawful search warrantsdorsetecho.co.uk · 8 Oct 2026Andrew locked in battle over evidence found through unlawful search warrantswirralglobe.co.uk · 8 Oct 2026Andrew locked in battle over evidence found through unlawful search warrantssouthwalesargus.co.uk · 8 Oct 2026BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026
12 headlines in the last 90 days name Andrew Lo; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.